Background: It is unclear whether the non–vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

Abstract Background Rivaroxaban (20 mg/15 mg once daily) is an effective and safe
alternative to warfarin for stroke prevention in patients with non-valvular AF (NVAF). Low …

Abstract Background: Low-dose rivaroxaban (10 mg/day) has been widely used in Asia for
patients with atrial fibrillation (AF), although there is a lack of evidence regarding its …

Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …

Background—The safety and effectiveness of non–vitamin K antagonist (VKA) oral
anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive …

BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …

Background No studies have directly compared the effectiveness and safety of dabigatran
and rivaroxaban using US Medicare data. Objective Our objective was to compare …

Aims The EXPAND study examined the real-world efficacy and safety of rivaroxaban for the
prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular …

Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …